Replimune Group Inc
NASDAQ:REPL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
PKSHA Technology Inc
TSE:3993
|
JP |
|
Justin Allen Holdings Ltd
HKEX:1425
|
CN |
|
ADDvantage Technologies Group Inc
OTC:AEYGQ
|
US |
Replimune Group Inc
Accrued Liabilities
Replimune Group Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Replimune Group Inc
NASDAQ:REPL
|
Accrued Liabilities
$40.3m
|
CAGR 3-Years
28%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accrued Liabilities
$8.2B
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accrued Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accrued Liabilities
$3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accrued Liabilities
$2.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
14%
|
CAGR 10-Years
19%
|
|
Replimune Group Inc
Glance View
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. The company is headquartered in Woburn, Massachusetts and currently employs 152 full-time employees. The company went IPO on 2018-07-20. The firm is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The firm applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The firm is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP1 (vusolimogene oderparepvec), RP2, and RP3. The firm is focused on Phase 2 clinical trials with its lead product candidate, RP1, in approximately 240 patients with a range of solid tumors.
See Also
What is Replimune Group Inc's Accrued Liabilities?
Accrued Liabilities
40.3m
USD
Based on the financial report for Dec 31, 2025, Replimune Group Inc's Accrued Liabilities amounts to 40.3m USD.
What is Replimune Group Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
39%
Over the last year, the Accrued Liabilities growth was 19%. The average annual Accrued Liabilities growth rates for Replimune Group Inc have been 28% over the past three years , 39% over the past five years .
